121 related articles for article (PubMed ID: 29474637)
21. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
22. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
[TBL] [Abstract][Full Text] [Related]
23. The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.
Suh DH; Park JY; Lee JY; Kim BG; Lim MC; Kim JW; Bae DS; Park SY; Nam JH; Kim K; No JH; Kim YB
Gynecol Oncol; 2015 Jun; 137(3):412-7. PubMed ID: 25868967
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
[TBL] [Abstract][Full Text] [Related]
25. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
26. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
Tamura R; Yoshihara K; Matsuo K; Yachida N; Miyoshi A; Takahashi K; Sugino K; Yamaguchi M; Mori Y; Suda K; Ishiguro T; Okuda S; Motoyama T; Nakaoka H; Kikuchi A; Ueda Y; Inoue I; Enomoto T
Gynecol Oncol; 2021 Nov; 163(2):327-333. PubMed ID: 34452748
[TBL] [Abstract][Full Text] [Related]
27. Suppressor-type TERT mutations associated with recurrence in ovarian clear cell carcinoma.
Kobayashi T; Nishikimi K; Mitsuhashi A; Piao H; Matsuoka A; Otsuka S; Tate S; Shozu M; Usui H
Genes Chromosomes Cancer; 2023 Aug; 62(8):471-476. PubMed ID: 36710084
[TBL] [Abstract][Full Text] [Related]
28. Endometriosis-associated Ovarian Cancers.
Anglesio MS; Yong PJ
Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
[TBL] [Abstract][Full Text] [Related]
29. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase (
Yoo H; Kim HS
Cancer Genomics Proteomics; 2023; 20(6):626-636. PubMed ID: 37889060
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
[TBL] [Abstract][Full Text] [Related]
32. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
33. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
[TBL] [Abstract][Full Text] [Related]
35. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
[TBL] [Abstract][Full Text] [Related]
36. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
Casuscelli J; Becerra MF; Manley BJ; Zabor EC; Reznik E; Redzematovic A; Arcila ME; Tennenbaum DM; Ghanaat M; Kashan M; Stief CG; Carlo M; Voss MH; Feldman DR; Motzer RJ; Chen Y; Reuter VE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2019 Jul; 5(4):642-649. PubMed ID: 28951115
[TBL] [Abstract][Full Text] [Related]
37. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
38. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
39. TERT promoter hotspot mutations in breast cancer.
Shimoi T; Yoshida M; Kitamura Y; Yoshino T; Kawachi A; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Ichimura K; Fukuda T; Fujiwara Y; Tamura K
Breast Cancer; 2018 May; 25(3):292-296. PubMed ID: 29222734
[TBL] [Abstract][Full Text] [Related]
40. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
